Aspergillus fumigatus and aspergillosis: From basics to clinics
Studies in Mycology · 01.09.2021 · 100 (1) · 100115-100115
DOI: 10.1016/j.simyco.2021.100115 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Studies in Mycology, erschienen am 01.09.2021. Verfasst von A Arastehfar und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA. Die Arbeit wurde bisher 239-mal zitiert (Crossref) und nennt 725 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The airborne fungus Aspergillus fumigatus poses a serious health threat to humans by causing numerous invasive infections and a notable mortality in humans, especially in immunocompromised patients. Mould-active azoles are the frontline therapeutics employed to treat aspergillosis. The global emergence of azole-resistant A . fumigatus isolates in clinic and environment, however, notoriously limits the therapeutic options of mould-active antifungals and potentially can be attributed to a mortality rate reaching up to 100 %. Although specific mutations in CYP 51A are the main cause of azole resistance, there is a new wave of azole-resistant isolates with wild-type CYP 51A genotype challenging the efficacy of the current diagnostic tools. Therefore, applications of whole-genome sequencing are increasingly gaining popularity to overcome such challenges. Prominent echinocandin tolerance, as well as liver and kidney toxicity posed by amphotericin B, necessitate a continuous quest for novel antifungal drugs to combat emerging azole-resistant A . fumigatus isolates. Animal models and the tools used for genetic engineering require further refinement to facilitate a better understanding about the resistance mechanisms, virulence, and immune reactions orchestrated against A . fumigatus . This review paper comprehensively discusses the current clinical challenges caused by A . fumigatus and provides insights on how to address them.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA.
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
- ICVS/3B's - PT Government Associate Laboratory, Guimarães/Braga, Portugal.
- Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.
- UCD Conway Institute and School of Medicine, University College Dublin, Dublin 4, Ireland.
- Department of Medicine, University of California San Diego, San Diego, CA, 92103, USA.
Zitieren
APA
Arastehfar, A., Carvalho, A., Houbraken, J., Lombardi, L., Garcia-Rubio, R., Jenks, J. D., Rivero-Menendez, O., Aljohani, R., Jacobsen, I. D., Berman, J., Osherov, N., Hedayati, M. T., Ilkit, M., Armstrong-James, D., Gabaldón, T., Meletiadis, J., Kostrzewa, M., Pan, W., Lass-Flörl, C., …, & Hoenigl, M. (2021). Aspergillus fumigatus and aspergillosis: From basics to clinics. Studies in Mycology, 100(1), 100115-100115. https://doi.org/10.1016/j.simyco.2021.100115
Vancouver
Arastehfar A, Carvalho A, Houbraken J, Lombardi L, Garcia-Rubio R, Jenks JD, et al. Aspergillus fumigatus and aspergillosis: From basics to clinics. Studies in Mycology. 2021;100(1):100115-100115. doi:10.1016/j.simyco.2021.100115
BibTeX
@article{Arastehfar2021,
author = {Arastehfar, A and Carvalho, A and Houbraken, J and Lombardi, L and Garcia-Rubio, R and Jenks, J D and Rivero-Menendez, O and Aljohani, R and Jacobsen, I D and Berman, J and Osherov, N and Hedayati, M T and Ilkit, M and Armstrong-James, D and Gabaldón, T and Meletiadis, J and Kostrzewa, M and Pan, W and Lass-Flörl, C and Perlin, D S and Hoenigl, M},
title = {Aspergillus fumigatus and aspergillosis: From basics to clinics},
journal = {Studies in Mycology},
year = {2021},
volume = {100},
number = {1},
pages = {100115--100115},
doi = {10.1016/j.simyco.2021.100115}
}
EUVIMED